Physician profile
Joseph William Mccollom
NPI 1467717520
$2,894.74
in general payments reported to CMS, 2019-2025
34 companies · $370 in 2025
The $370 reported for 2025 was more than what 89% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $391 · 2021: $321 · 2022: $264 · 2023: $302 · 2024: $506 · 2025: $370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,113 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,112.82 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Histosonics, INC. | $316.92 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $300.43 | 2019-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $249.91 | 2019-2025 | Keytruda, Keytruda Qlex |
| Seagen INC. | $170.05 | 2023 | Tukysa, Padcev |
| Astrazeneca Pharmaceuticals Lp | $166.40 | 2020-2023 | |
| Boston Scientific Corporation | $154.74 | 2020 | |
| Amgen INC. | $137.69 | 2019-2020 | |
| Celgene Corporation | $136.46 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $135.54 | 2019-2022 | |
| Acrotech Biopharma INC. | $120.35 | 2022 | |
| Rigel Pharmaceuticals, INC. | $114.63 | 2019-2021 | |
| Janssen Biotech, INC. | $103.57 | 2024-2025 | Akeega, Erleada, Balversa |
| Genentech USA, INC. | $102.31 | 2019 | |
| Incyte Corporation | $92.00 | 2021 | |
| Eisai INC. | $65.55 | 2019-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $58.40 | 2019-2025 | Cabometyx |
| Genzyme Corporation | $50.72 | 2019-2020 | |
| Pfizer INC. | $45.53 | 2024 | |
| Emd Serono, INC. | $43.23 | 2023-2024 | Bavencio |
| Pharmacosmos Therapeutics INC. | $42.74 | 2025 | Monoferric |
| Abbvie INC. | $41.84 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $34.84 | 2023 | Erleada, Balversa, Abiraterone Acetate |
| Tempus Ai, INC | $28.83 | 2024 | |
| Puma Biotechnology, INC. | $21.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.77 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $18.20 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.11 | 2020 | |
| Kyowa Kirin, INC. | $16.90 | 2020 | |
| Astellas Pharma Global Development | $15.17 | 2025 | Vyloy |
| Agios Pharmaceuticals, INC. | $14.37 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.37 | 2019 | |
| Dendreon Pharmaceuticals LLC | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mccollom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.